Guest Editors
Dr. Mihnea-Alexandru Găman
Email: mihneagaman@yahoo.com
Affiliation: Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, Bucharest, 050474, Romania.
Homepage:
Research Interests: Myeloproliferative neoplasms, Acute leukemia, Multiple myeloma, Lymphoma
Summary
Hematological malignancies, including leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and myelodysplastic neoplasms, pose significant challenges in oncology due to their complexity, heterogeneity, and treatment resistance. In recent years, advancements in OMICS technologies, artificial intelligence, and precision medicine have revolutionized the understanding of these diseases, leading to the identification of novel biomarkers and the development of targeted therapies. Biomarkers play a critical role in early diagnosis, risk stratification, treatment selection, and disease monitoring, ultimately improving patient outcomes.
Despite these advancements, patients with high-risk features or those exposed to multiple lines of therapy often face poor prognosis, underscoring the need for continued research into more effective and personalized therapeutic strategies. This Special Issue aims to highlight recent progress in biomarker discovery and targeted therapies for blood cancers, with a particular focus on molecular targets, prognostic and predictive biomarkers, and innovative treatment approaches. We welcome original research and review articles that explore both translational and clinical applications, ultimately contributing to the advancement of precision oncology in hematological malignancies.
Keywords
Leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, myelodysplastic neoplasms, hematological malignancies, blood cancers, oncology, hematology
Login
Register
Submit a Paper
Propose a Special lssue